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Abstract
The French, American, and British (FAB) classiﬁcation system for acute myeloid leukemia (AML) is
extensively used and is incorporated into the AML, not otherwise speciﬁed (NOS) category in the
2016 WHO edition of myeloid neoplasm classiﬁcation. While recent data proposes that FAB clas-
siﬁcation does not provide additional prognostic information for patients for whom NPM1 status is
available, it is unknown whether FAB still retains a current prognostic role in predicting outcome
of AML patients undergoing allogeneic stem cell transplantation. Using the European Society of
Blood and Bone Marrow Transplantation registry we analyzed outcome of 1690 patients trans-
planted in CR1 to determine if FAB classiﬁcation provides additional prognostic value. Multivariate
analysis revealed that M6/M7 patients had decreased leukemia free survival (hazard ratio (HR) of
1.41, 95% conﬁdence interval (CI), 1.01–1.99; P 5 .046) in addition to increased nonrelapse mor-
tality (NRM) rates (HR, 1.79; 95% CI, 1.06–3.01; P 5 .028) compared with other FAB types. In the
NPM1wt AML, NOS cohort, FAB M6/M7 was also associated with increased NRM (HR, 2.17; 95%
CI, 1.14–4.16; P 5 .019). Finally, in FLT3-ITD1 patients, multivariate analyses revealed that speciﬁc
FAB types were tightly associated with adverse outcome. In conclusion, FAB classiﬁcation may
predict outcome following transplantation in AML, NOS patients.
1 | INTRODUCTION
Prognostication plays a major role in clinical decision-making for
patients with acute myeloid leukemia (AML). With the advent of wide-
spread high throughput molecular sequencing platforms, assessment of
FLT3 and NPM1 mutational status has become a standard major deter-
minant in predicting patient outcome. As ASCT is associated with sig-
niﬁcant rates of attendant toxicity and mortality,1 eﬀorts to better
prognosticate and risk stratify patients before transplant are of prime
importance. Previous eﬀorts aiming at delineating the role FLT3-ITD
status2–8 and NPM1 status9–11 play in determining clinical outcome fol-
lowing ASCT have yielded conﬂicting results, thus underscoring the
need for improved prognostication of candidates for ASCT. The
French-American-British (FAB) classiﬁcation system has been
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traditionally used to classify AML into discrete types designated M0-
M7, and notwithstanding the incorporation of new molecular catego-
ries into the recent 2016 rendition of the world health organization
(WHO) myeloid neoplasms classiﬁcation,12 FAB classiﬁcation is still a
core feature of the large WHO category of AML, not otherwise speci-
ﬁed (NOS) patients. While earlier studies suggested a prognostic role
for speciﬁc FAB types,13–17 the prognostic role FAB classiﬁcation holds
in current practice has been recently questioned by Walter et al. who
propose that when NPM1 and CEBPA status is available, FAB no longer
predicts patient outcome.18 Yet, it remains unclear whether in patients
undergoing allogeneic stem cell transplant (ASCT) in complete remis-
sion (CR1), FAB still holds prognostic signiﬁcance. To this end, using
the European Society of Blood and Bone Marrow Transplantation
(EBMT) registry, we set out to determine whether FAB classiﬁcation
still retains a signiﬁcant role in the current era of advanced molecularly
incorporated classiﬁcation systems of AML.
2 | PATIENTS AND METHODS
2.1 | Study population
Data were provided, and the study design was approved by the acute
leukemia working party (ALWP) of the EBMT group registry, in accord-
ance with the EBMT guidelines for retrospective studies. EBMT is a
voluntary working group of more than 500 transplant centers which
are required to report all consecutive stem cell transplantations and
follow-up once a year. Audits are routinely performed to determine the
accuracy of the data. Using the EBMT registry we identiﬁed patients
with available FAB data and the following inclusion criteria: (1) age
over 18, (2) de novo non-M3 AML, and (3) ASCT in complete remission
(CR1) from a fully matched sibling or a 10/10 human leukocyte antigen
(HLA) matched unrelated donor. Patients with recurrent genetic abnor-
malities, AML with myelodysplasia-related changes, and patients with
therapy-related myeloid neoplasms were excluded from the analysis.
2.2 | Endpoint deﬁnitions
The primary end points were leukemia-free survival (LFS), relapse inci-
dence (RI), nonrelapse mortality (NRM), and overall survival (OS).
\Secondary end points were engraftment, acute and chronic graft-
versus-host disease (GVHD). LFS was deﬁned as survival with no
evidence of relapse or progression. Relapse was deﬁned as the reap-
pearance of 5% bone marrow blasts and/or extramedullary lesion due
to speciﬁc blast cell inﬁltration. NRM was deﬁned as death without evi-
dence of relapse or progression. OS was deﬁned as the time from
ASCT to death, regardless of the cause.
2.3 | Statistical analysis
Multivariate analyses were used to assess whether the FAB type was
independently associated with LFS, OS, RI, and NRM. Age, gender,
cytogenetics, donor type, FMS-like tyrosine kinase-3 internal tandem
duplication (FLT3-ITD) status, nucleophosmin (NPM1) status, and condi-
tioning intensity were covariates for regression modeling. Cytogenetic
risk groups were deﬁned according to established criteria.19 LFS was
deﬁned as time interval from ASCT until either relapse or death in
months, and was calculated using the Kaplan-Meier estimate. NRM
was deﬁned as death in the absence of relapse. RI and NRM were cal-
culated using cumulative incidence curves in a competing risks setting,
death in remission being treated as a competing event to relapse and
relapse in the NRM estimation setting, respectively. Univariate analyses
were performed using log rank test for OS and LFS while Gray’s test
was applied for RI and NRM. A Cox proportional hazards model was
used for multivariate regression. Variables diﬀering in terms of distribu-
tion between the groups and factors conceptually important were
included in the model. Results are expressed as hazard ratio (HR) with
95% conﬁdence interval (CI). All tests were two-sided. The type I error
rate was ﬁxed at 0.05 for determination of factors associated with time
to event outcomes.
Statistical analyses were performed with SPSS 19 (SPSS Inc., Chi-
cago, USA) and R (R Development Core Team, Vienna, Austria) soft-
ware packages.
3 | RESULTS
3.1 | Patient characteristics
A cohort of 1690 patients who were transplanted between 2005 and
2014 was identiﬁed and analyzed; baseline characteristics are shown in
Table 1. The median age was 50 years (range, 18–74 years) with a
median follow-up duration of 34.7 months. Patients with M6 and M7
were signiﬁcantly older compared with patients with other FAB types.
M7 patients also had an increased rate of poor risk cytogenetics (60%)
although we note the small number of patients in this category (n 5
10) may limit interpretation of this observation. Patients with M2 and
M4 had the highest rates of mutated FLT3-ITD (54.6% and 53.6%,
respectively) while the group of M4 patients was noted to have the
highest prevalence of NPM1 mutations (53% versus 38.6% for the
entire cohort). Donor type and conditioning intensity did not diﬀer to a
signiﬁcant degree between the diﬀerent FAB types.
3.2 | Impact of FAB category on clinical outcome in
the complete cohort
To assess the impact of FAB category on patient outcome we initially
analyzed the cohort as a whole, namely irrespective of NPM1 and
FLT3-ITD status. In univariate analysis there was no signiﬁcant associa-
tion of FAB category with clinical outcome following transplant, speciﬁ-
cally rates of LFS, OS, RI, and NRM were comparable between the
diﬀerent FAB subtypes (Supporting Information Table 1). Since M6 and
M7 patients comprised together the smallest group of patients in our
cohort (n 5 75), a reanalysis comparing the composite of M6/M7
patients to M0-M5 patients was performed. In univariate analysis M6/
M7 patients had increased 1 year (15.6% [8.2–25] versus 9.5% [8.1–
11.1]) and 3 years (24.1% [13.9–35.7] versus 13.7% [11.9–15.6]) (P 5
0.0291) NRM rates compared with non-M6/M7 patients, while LFS,
OS, and RI did not diﬀer to a signiﬁcant degree between groups. To
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account for the possible inﬂuence of additional factors on the impact
of FAB subtype on clinical outcome, a multivariate analysis was under-
taken using the following covariates: age, gender, cytogenetic risk cate-
gory, donor type, FLT3-ITD status, NPM1 status, and conditioning
intensity. As shown in Table 2 and Figure 1, M6/M7 patients had
decreased LFS and increased NRM rates (HR51.41 [1.01–1.99],
P5 .046; and HR51.79 [1.06–3.01], P5 .028 respectively), although
these did not translate into a change in overall survival.
3.3 | Impact of FAB classiﬁcation on clinical outcome
in NPM1wt “AML, NOS” patients
Next, to align our data with the recently introduced 2016 WHO AML,
NOS classiﬁcation which comprises AML patients who lack any of the
following: recurrent genetic abnormalities, mutated NPM1, biallelic
mutations of CEBPA, myelodysplasia-related changes or therapy
related AML, we restricted our analysis to the NPM1wt subset of the
cohort (n 5 712). Patients with unknown NPM1 status were excluded
from the analysis. The characteristics of this cohort are summarized in
Supporting Information Table 2, notably FAB M7 and M5 patients
were more likely to have poor risk cytogenetics (57.1% and 35.5%
respectively), and additionally M4 patients were more likely to be
FLT3-ITD1/NPM1wt (26.6% vs. 16.9% for the entire cohort). Subse-
quently, a multivariate regression analysis was performed, and as sum-
marized in Table 3 and Supporting Information Figure 1 showed that in
AML, NOS NPM1wt patients, FAB M6/M7 category was signiﬁcantly
associated with increased NRM (HR52.17 [1.14–4.16], P5 .019). We
also note that on additional analysis, upon comparing M6/M7 to the
other FAB types individually, we observed that M6/M7 compared with
M0 was signiﬁcantly associated with decreased LFS (HR51.88 [1.02–
3.48], P5 .045), increased NRM (HR52.7 [1.05–6.93], P5 .039), and a
trend towards decreased OS (HR51.87 [0.96–3.64], P5 .066).
3.4 | Association of FAB category with clinical
outcome in FLT3-ITD1 patients following ASCT
Given the known association of FLT3-ITD1 status with deleterious out-
come in AML in general and post-transplant,7,8 we wondered whether
FAB classiﬁcation would have additional prognostic value in this spe-
ciﬁc patient population (n 5 356). The characteristics of this cohort are
summarized in Supporting Information Table 3.
Univariate analysis indicated that M4 patients had a signiﬁcantly
lower 1 year OS rate of 64% (95% CI [56–73], P 5 .0345) and a lower
3-year OS rate of 49.1% (95% CI [40.6–59.4], P 5 .0345).
As shown in Supporting Information Table 4 in which M0 serves
as the reference considered to have a hazard ratio of 1.0, a multivariate
analysis conﬁrmed that FAB types M2 and M4 were independently
associated with decreased LFS rates whereas M4 and M6/M7 had
lower OS rates, and M2 patients had an increased likelihood of RI.
There was no statistically signiﬁcant diﬀerence in outcome between
M6/M7 patients and non M6/M7 patients in the FLT3-ITD1 cohort
(Supporting Information Figure 2).
4 | DISCUSSION
In the present analysis of 1690 AML patients undergoing allogeneic
stem cell transplantation in CR1, we present data supporting a contem-
porary role for FAB classiﬁcation in the prediction of post-
transplantation outcome. Our ﬁndings indicate that in speciﬁc patient
subsets; eg M6/M7 in an unselected cohort, M6/M7 in the strictly
deﬁned AML, NOS NPM1wt subset, and M6/M7 in FLT3-ITD1 patients,
FAB classiﬁcation has a substantial prognostic value in predicting
adverse outcome following allogeneic transplantation.
Since its introduction in the 1970s, FAB classiﬁcation has played a
central role in classiﬁcation and to some degree prognostication of
TABLE 2 Multivariable analysis of the entire cohort for clinical outcome
Parameter
Leukemia-free survival HR
(95% CI)
Overall survival
HR (95% CI)
Relapse incidence
HR (95% CI)
Nonrelapse mortality
HR (95% CI)
FAB classiﬁcation (M6/M7
us. non M6/M7)
1.41 (1.01–1.99), P5 .046 1.28 (0.89–1.85), P5 .19 1.22 (0.77–1.92), P5 .39 1.79 (1.06–3.01), P5 .028
Female gender 0.89 (0.76–1.04), P5 .15 0.89 (0.75–1.05), P5 .16 0.86 (0.71–1.04), P5 .12 0.97 (0.74–1.26), P5 .8
Age (10-year increment) 1.13 (1.05–1.21), P5 .001 1.22 (1.13–1.32), P< .0001 1.04 (0.95–1.14), P5 .4 1.33 (1.17–1.52), P< .0001
Donor (unrelated 10/10
vs. HLA identical sibling)
1.00 (0.85–1.18), P5 .96 1.07 (0.9–1.27), P5 .47 0.87 (0.71–1.07), P5 .2 1.3 (0.99–1.71), P5 .063
Cytogenetic risk status
(poor vs. intermediate)
1.55 (1.26–1.89), P< .0001 1.65 (1.34–2.04), P< .0001 1.71 (1.34–2.18), P< .0001 1.22 (0.85–1.76), P5 .27
FLT3-ITD status
(present vs. absent)
0.74 (0.58–0.93), P5 .011 0.72 (0.56–0.92), P5 .009 0.77 (0.58–1.02), P5 .068 0.69 (0.46–1.04), P5 .073
NPM1 status
(mutated vs. wild type)
1.06 (0.88–1.28), P5 .54 1.08 (0.89–1.31), P5 .45 1.03 (0.82–1.3), P5 .78 1.13 (0.82–1.55), P5 .45
Conditioning intensity
(RIC vs. MAC)
1.01 (0.84–1.21), P5 .91 1.00 (0.82–1.21), P5 .98 1.18 (0.94–1.47), P5 .15 0.74 (0.54–1.01), P5 .056
Abbreviations: FLT3-ITD, FMS-like tyrosine kinase-3 internal tandem duplication; MAC, myeloablative conditioning; NPM1, nucleophosmin; RIC,
reduced intensity conditioning.
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AML.20–22 Subsequently it underwent modiﬁcations to accommodate
for advances made in immunophenotyping, cytogenetics, and molecu-
lar genetics.23,24 While the most recent edition of the World Health
Organization classiﬁcation of myeloid neoplasms and acute leukemia,12
places emphasis on molecular categorization of AML, eg, the addition
of the two new categories of AML with mutated NPM1, and AML
with biallelic mutations of CEBPA (and the provisional entities of AML
with mutated RUNX1 or BCR-ABL1), FAB is still incorporated into the
AML, NOS category which comprises most of the AML patient
population.
TABLE 3 Multivariable analysis of AML, NOS NPM1wt for clinical outcome
Parameter
Leukemia-free survival
HR (95% CI)
Overall survival
HR (95% CI)
Relapse incidence
HR (95% CI)
Nonrelapse mortality
HR (95% CI)
FAB classiﬁcation
(M6/M7 vs. non-M6/M7)
1.48 (0.94–2.33), P 5 .093 1.43 (0.88–2.35), P 5 .15 1.1 (0.57–2.1), P 5 .78 2.17 (1.14–4.16), P 5 .019
Female gender 0.79 (0.61–1.02), P 5 .071 0.81 (0.62–1.06), P 5 .12 0.76 (0.56–1.04), P 5 .088 0.84 (0.54–1.29), P 5 .43
Age (10-year increment) 1.15 (1.02–1.29), P 5 .019 1.25 (1.1–1.42), P 5 .0007 1.08 (0.93–1.24), P 5 .31 1.3 (1.06–1.6), P 5 .012
Donor (unrelated 10/10
vs. HLA identical sibling)
1.08 (0.83–1.39), P 5 .57 1.17 (0.89–1.53), P 5 .27 0.92 (0.66–1.26), P 5 .59 1.42 (0.93–2.16), P 5 .11
Cytogenetic risk status
(poor vs. intermediate)
1.45 (1.07–1.95), P 5 .015 1.68 (1.24–2.29), P 5 .0009 1.83 (1.28–2.6), P 5 .0009 0.86 (0.49–1.52), P 5 .61
FLT3–ITD status
(present vs. absent)
1.96 (1.45–2.65), P< .0001 1.65 (1.18–2.3), P 5 .003 2.35 (1.64–3.36), P< .0001 1.33 (0.77–2.31), P 5 .31
Conditioning intensity
(RIC vs. MAC)
0.98 (0.73–1.32), P 5 .91 1.04 (0.76–1.42), P 5 .82 1.11 (0.77–1.61), P 5 .58 0.76 (0.46–1.26), P 5 .29
Abbreviations: FLT3-ITD, FMS-like tyrosine kinase-3 internal tandem duplication; MAC, myeloablative conditioning; NPM1, nucleophosmin; RIC,
reduced intensity conditioning; WT, wild type.
FIGURE 1 Outcome of FAB M6/M7 patients compared with other FAB types following ASCT. A, Relapse incidence (RI) after ASCT. B,
Nonrelapse mortality (NRM). C, Leukemia-free survival (LFS). D, Overall survival (OS) after ASCT. Adjusted for age, gender, donor type,
cytogenetic risk, FLT3-ITD status, NPM1 status, and conditioning regimen. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
348 | AJH CANAANI ET AL.
In early studies looking at the prognostic role of FAB in the setting
of allogeneic transplantation, M4 and M5 FAB subtypes were found to
be associated with an increased relapse rate, 58% versus the 9% seen in
M1-M3.15 In the same vein, registry data from EBMT also established
FAB M4 and M5 as adverse risk factors predicting for leukemia
relapse.16 Data published nearly a decade later showed that in a cohort
of 91 patients undergoing transplant in CR1 from HLA-identical siblings,
overall survival was inferior in M4-M6 FAB subtypes, and transplant-
related mortality was increased in FAB M4-M6 patients.17 More recent
data in postautologous transplantation patients also supports a prognos-
tic role for FAB classiﬁcation, wherein M0/M6/M7 patients experi-
enced signiﬁcantly decreased overall survival compared with M1-M5
patients.14 Our experience diﬀers from that published by the European
and Italian cooperative groups in the EORTC-GIMEMA AML 8A trial
where 169 patients underwent ASCT in CR1 and where FAB type was
not found to be of prognostic importance.25 However, we do note that
given our much larger and more recent cohort, our data may reﬂect
more accurately the typical contemporary transplant patient population.
Additionally, the aforementioned study did not have molecular data
which undoubtedly adds prognostic depth to our analysis.
Interestingly, most of the literature examining the role of FAB in
predicting outcome of AML patients treated with chemotherapy only
regimens or at least not analyzed speciﬁcally for transplant, does not
indicate a prognostic role for FAB classiﬁcation. Earlier published data
from the Eastern Cooperative Oncology Group focusing on outcome of
M5 versus non-M5 patients also did not support a prognostic role for
FAB classiﬁcation, although only seven patients (from a total of 81)
underwent allogeneic transplantation in this analysis, thus limiting the
ability to interpret data from a transplant standpoint.26 More recently,
Walter et al. performed a comprehensive analysis of the combined data-
sets of several large cooperative groups in U.S. and Europe and deter-
mined that FAB M0 was associated with inferior rates of attainment of
a complete remission following induction chemotherapy resulting in
poorer relapse-free and overall survival rates. Notably, upon restricting
their analysis to NPM1wt (and also NPM1wt/CEBPA-) patients this associ-
ation was no longer meaningful.18 These data diﬀer to some degree
from ours which might be expected when considering the inherent dif-
ferences in cohort composition where ours consisted only of trans-
planted patients while Walter et al. did not have access to transplant
data. The divergence in cohort composition and consequently results is
also reﬂected in the diﬀerence in patient age noted by our groups,
namely in our analysis M6/M7 patients were older compared with other
FAB types while in theWalter analysis it was the M0 patients who were
oldest. Similar to what we noted, their data regarding M7were also sug-
gestive of inferior clinical outcome, although given the small number of
M7 patients (0.1% of the total cohort) they were unable to draw ﬁrm
conclusions regarding the prognostic role of FABM7.
In addition to the diﬀerent study populations (transplanted vs.
unknown) analyzed, the diﬀerence in the results of both studies may
be also accounted by acknowledgment of the diﬀerent complementary
molecular data used, ie, FLT3-ITD compared with CEBPA testing.
An additional salient point we establish is that in FLT3-ITD1
patients, consideration of FAB type augments patient risk stratiﬁcation
by identifying FAB M2 patients as those with increased relapse inci-
dence, as well as recognizing that M2 and M4 patients as those with
decreased leukemia free survival rates. This is of considerable value as
most clinicians today would consider allogeneic stem cell transplant the
preferred therapeutic approach for ﬁt FLT3-ITD1 patients,27,28 yet even
within the patient population positive for FLT3-ITD, relapse risk varies,
further emphasizing the need to carefully select patients for whom
transplant would be beneﬁcial in terms of the risk to beneﬁt ratio.
Recently published data also aiming to stratify FLT3-ITD patients being
transplanted indicates that patients with a low FLT3-ITD mutation bur-
den (quantiﬁed by the FLT3-ITD mutant to wild-type allelic ratio) do not
derive a clinical beneﬁt from an ASCT in terms of RFS and OS.29 How-
ever, this assay may be limited by low sensitivity, heterogeneous meth-
odologies, and diverse cutoﬀ values used by diﬀerent centers.27
Additionally, our data may better inform clinicians in selecting higher
risk patients who may beneﬁt from enrollment into ongoing and future
clinical trials with FLT3 targeted maintenance therapy post-transplant.
Given the inherent limitation of a retrospective analysis it may be dif-
ﬁcult to determine why FAB M6/M7 patients have decreased leukemia
free survival and increased nonrelapse mortality, yet considering that M6
is commonly associated with poor-risk cytogenetics may provide a partial
explanation for this clinical phenotype30 as well as recognizing that FAB
M7 has the highest frequency of cytogenetic aberrations among all FAB
categories.31 Nevertheless, we do acknowledge that these would not fully
explain the increased non-relapse mortality rates observed in our study.
We recognize several limitations in our analysis. First, the retro-
spective nature of this study with the inherent limitations seen in com-
parable analyses. Second, our registry is not fully annotated for CEBPA
thus limiting our ability to fully characterize the role of FAB classiﬁca-
tion per the recently revised WHO classiﬁcation. Lastly, the relative
infrequency of FAB M6/M7 in general and speciﬁcally in our analyzed
cohort may also limit interpretation of our data.
In aggregate, our ﬁndings in a large cohort of transplanted patients
suggest that FAB classiﬁcation contributes and enhances the prognos-
tic capacity of molecular data provided by FLT3-ITD and NPM1 muta-
tional status. Our ﬁndings support the continued use of FAB
classiﬁcation to complement molecular data in AML patients under-
going allogeneic stem cell transplantation.
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